» Articles » PMID: 20547457

Mammographic Surveillance in Women with a Personal History of Breast Cancer: How Accurate? How Effective?

Overview
Journal Breast
Publisher Elsevier
Specialties Endocrinology
Oncology
Date 2010 Jun 16
PMID 20547457
Citations 26
Authors
Affiliations
Soon will be listed here.
Abstract

We review the accuracy and potential effect of mammography in surveillance of women with a personal history of breast cancer (PHBC). A literature review was performed to identify studies on screening mammography or breast surveillance reporting data on the accuracy or detection capability of mammography, or the effect of early detection of second breast cancers, in women with a PHBC. Evidence on mammography screening in women with PHBC comes from non-randomised studies, and is generally limited by several factors including design limitations. The proportion of ipsilateral breast recurrences detected with mammography ranges between 50% and 80% (including cancers detected also on clinical examination) but is lower at 8%-51% for mammography-only detection. Mammography detects approximately 45%-90% of contralateral cancers. There is evidence of a potential benefit for asymptomatic/early-detected second breast cancers (range of estimated hazard ratios: 0.10-0.86) relative to symptomatic or clinical-detection, in various surveillance strategies that include mammography, however these estimates are likely to have overestimated screening benefit. New evaluations of screening women with a PHBC are needed from screening programs or population datasets, to provide comprehensive measures of screening accuracy and outcomes in this population of women.

Citing Articles

Breast cancer recurrence in relation to mode of detection: implications on personalized surveillance.

Sartor H, Hagberg O, Hemmingsson O, Lang K, Wadsten C Breast Cancer Res Treat. 2024; 209(1):85-92.

PMID: 39251456 PMC: 11785654. DOI: 10.1007/s10549-024-07475-8.


Current State of Evidence-Based Long-Term Monitoring Protocols for Breast Plastic Surgery Patients.

Ho I, Chichura A, Pederson H, Xavier B, Ritner J, Schwarz G Ann Surg Oncol. 2024; 31(12):8372-8382.

PMID: 39103688 PMC: 11466996. DOI: 10.1245/s10434-024-16003-3.


Diagnostic Value of FDG PET/CT in Surveillance after Curative Resection of Breast Cancer.

Lee H, Choi J, Park Y, Lee J, Kim S, Nam S Cancers (Basel). 2023; 15(9).

PMID: 37174111 PMC: 10177223. DOI: 10.3390/cancers15092646.


Performance of Statistical and Machine Learning Risk Prediction Models for Surveillance Benefits and Failures in Breast Cancer Survivors.

Su Y, Buist D, Lee J, Ichikawa L, Miglioretti D, Aiello Bowles E Cancer Epidemiol Biomarkers Prev. 2023; 32(4):561-571.

PMID: 36697364 PMC: 10073265. DOI: 10.1158/1055-9965.EPI-22-0677.


Routine and interval detection of locoregional breast cancer recurrences and risk of subsequent distant metastasis.

Eijkelboom A, de Munck L, de Vries M, Francken A, Hendriks M, Strobbe L Breast Cancer Res Treat. 2022; 197(1):123-135.

PMID: 36315307 PMC: 9823019. DOI: 10.1007/s10549-022-06757-3.